Patients
This singer-center, prospective clinical study (ChiCTR2100046762) was conducted from June 1st, 2021 to July 15 at Fudan University Shanghai Cancer Center. The study was approved by the hospital’s Ethical Committee (No. 2104233-4) and all patients enrolled were informed about the clinical trial and willing to participate.
40 patients were included. The inclusion criteria were: 1) Over 18 years old; 2) Tachycardia, mean arterial pressure of < 75 mmHg, stroke volume or variation in pulse pressure of > 12%, the pressure of central venous or right atrial pressure of < 5 mmHg, mixed venous oxygen saturation < 70%; 3) Based on the patient's gender, age, and body temperature, the actual cardiac output was lower than the expected output.
Patients were excluded if they have increased intra-abdominal pressure (IAP (intra-abdominal pressure) of > 12 mmHg)), arrhythmia, pulmonary hypertension, severe heart valve disease, severe thoracic aortic anatomy, external cardiac pacemaker, head trauma, severe heart failure patients, patients with thrombotic stockings, and uncooperative patients. Moreover, those who are not suitable for enrollment due to other reasons, such as patients with clear hemorrhage or active bleeding, and patients who need immediate rescue.
Study design and measurements
Figure 1. illustrates the protocol steps of current study. Hemodynamic variables, such as heart rate, pulse pressure variation (PPV), systolic blood pressure, central venous pressure (CVP), CI, stroke volume variation (SVV), mean arterial pressure, stroke volume index (SVI) along with diastolic blood pressure, were recorded.
Hemodynamic variables were measured during six sequential steps (Fig. 2.). The initial set of assessments was acquired at a semi-recumbent position (45°) (named as base 1), ensuring that the detected value is stable.
Then we performed a unilateral PLR test, the unilateral lower limbs were then raised at an 45° angle while the patients’ trunk and other side of lower limbs were in supine posture. Therefore, the angle of the trunk with the lower limbs remained unaltered at 135°. A second assessment set (named unilateral PLR) was documented at the maximal effect of unilateral PLR on CI, which occurs within 1 minute.
The body position was then rendered to the base 1 posture and the CI return to its baseline value, then a third assessment set was documented (base 2).
To prevent possible pain from creating false positives, the automatic technique was used for bed elevation. The patients’ lower limbs were lifted to a 45° angle from the horizontal position, whereas the trunk was lowered in a horizontal position, and the angle of the trunk and the leg is still 135°. The fourth set of values (termed bilateral PLR) were measured, when the CI reached its maximal value. Maximal impact on PLR on CI was detected within 1 min in all patients.
The position was sent back to base 1, then the fifth set of assessments was documented (base 3).
Finally, measurements were acquired after volume expansion (VE) (500 mL of saline more than 15 min) (designated post-VE).
The CVP was measured at each study step, evaluated the jugular venous pulse was to estimate CVP[12]. CVP was decided at end-expiration and demonstrated the averaged value from three sequential respiratory cycles.
Hemodynamic monitoring
The ProAQT/Pulsioflex (Pulsion Medical Systems, Munich, Germany, termed as ‘Pulsioflex’ hereafter) is a novel pulse contour assessment instrument that does not require external interference, calibration of pressure waveform assessment.
Monnet et al. investigate Pulsioflex’s ability to monitor modifications in CI that were triggered by a rise expansion of volume or decrease in norepinephrine dosage in 60 study subjects at the department of intensive care. They discovered that the Pulsioflex was capable of keeping track of the changes in CI that were triggered by the expansion of volume (as illustrated by a concordance rate close of to 95%). For monitoring fluid-triggered alterations in CI, the Pulsioflex was trustworthy[13].
A radial arterial catheter was connected to Pulsioflex to observe SVI, SVV, and PPV. Cardiac output’s initial value was assessed with a proprietary algorithm conducting an “auto-calibration”. The stroke volume at that point was calculated using pulse contour assessment. PPV along with SVV was continuously shown on the Pulsioflex screen. SVI, SVV, CI, as well as PPV estimations utilizing Pulsioflex are a mean over the last 12 s and are modernized every second. SVI, CI, PPV, and SVV are shown beat-to-beat in the form of a "sliding average” of 12 s. When extracting information through a USB harbor to an Excel file, values were shown every 12 s.
Statistical analysis
After completing of the study protocol, patients were divided into two groups: responders and non-responders to fluid loading.
Patients with CI increase more than 15% by volume expansion from base 3 were classified as responders, otherwise, as non-responders.
The data distribution normality was screened with the Kolmogorov-Smirnov examination. Data are presented as mean [standard deviation (SD)], median (interquartile range), or number (frequency in %).
The comparison of patient’s characteristics, medical history, and cause of circulatory failure between responders and non-responders was performed using a nonparametric Mann–Whitney U test for continuous variables and a chi-square test for categorical variables.
Comparison of hemodynamic variables between time points of the study was performed by paired Student’s t-test or Wilcoxon test, based on the data distribution. Comparison between volume responders and non-responders was performed using the two-sample Student’s t-test or the Mann-Whitney U-test, as appropriate.
Receiving operating characteristic (ROC) curves were produced for unilateral PLR-induced changes in continuous variables (CI, PPV, SVI and SVV). The area under the ROC curves for unilateral PLR-triggered changes of CI and bilateral PLR-triggered changes of CI were compared in all patients using a Hanley-McNeil test[14].
A two-tailed p-value < 0.05 showed statistical significance. Statistical analysis was implemented in the MedCalc Statistical Software version 19.0.4 (MedCalc Software bvba, Ostend, Belgium; https://www.medcalc.org; 2019).